These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20625290)

  • 1. Aldosterone blockade in chronic kidney disease: can it improve outcome?
    Toto RD
    Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):444-9. PubMed ID: 20625290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
    Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ
    Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S; Bigazzi R; Campese VM
    Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 33358451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptor blockers and chronic kidney disease.
    Jain G; Campbell RC; Warnock DG
    Clin J Am Soc Nephrol; 2009 Oct; 4(10):1685-91. PubMed ID: 19729430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone blockade in CKD: emphasis on pharmacology.
    Schwenk MH; Hirsch JS; Bomback AS
    Adv Chronic Kidney Dis; 2015 Mar; 22(2):123-32. PubMed ID: 25704349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
    Barrera-Chimal J; Girerd S; Jaisser F
    Kidney Int; 2019 Aug; 96(2):302-319. PubMed ID: 31133455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid antagonists in chronic kidney disease.
    Dhaybi OA; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Jan; 26(1):50-55. PubMed ID: 27753685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
    Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
    Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Roll of aldosterone in pathogenesis of kidney disorders].
    Kitamura K; Tomita K
    Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1428-34. PubMed ID: 16097603
    [No Abstract]   [Full Text] [Related]  

  • 19. Aldosterone in the pathogenesis of chronic kidney disease and proteinuria.
    Lu Y; Ku E; Campese VM
    Curr Hypertens Rep; 2010 Aug; 12(4):303-6. PubMed ID: 20596805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.